

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Simvastatine in the treatment of negetive symptoms in stable schizophrenia: a double blind and randomised clinical trial

Protocol summary

s.akhond@sina.tums.ac.ir

Summary

The objective of this randomized, double-blind, placebo controlled study is to test the hypothesis that the addition of Simvastatin would improve psychopathology in subjects with schizophrenia treated with Risperidone. 50 patients with chronic DSM-5-diagnosed schizophrenia will receive Risperidone (4-6 mg/day) combined with either placebo (N=25) or 40 mg/day of Simvastatin (N=25) for 8 weeks. Efficacy will be defined as the change from baseline to endpoint in score on the Positive and Negative Syndrome Scale (PANSS). Side effects will be also evaluated using checklist and Extra-pyramidal Symptoms Rating Scale.

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2014-11-22, 1393/09/01

Expected recruitment end date

2016-11-20, 1395/08/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201410021556N65**

Registration date: **2014-10-28, 1393/08/06**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2014-10-28, 1393/08/06

Registrant information

Name

Shahin Akhondzadeh

Name of organization / entity

Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 5541 2222

Email address

Scientific title

Simvastatine in the treatment of negetive symptoms in stable schizophrenia: a double blind and randomised clinical trial

Public title

Simvastatine in the treatment of schizophrenia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion Criteria:1-Diagnosis of Schizophrenia based on DSM- 5 criteria;2- Minimum Score of 20 in negative subscale of Positive and Negative Scale(PANNS) 3- Age between 18-50; 4- chronic Schizophrenia- duration of the disorder more than 2 years; ; Exclusion Criteria:1-any other mental disorder on axis I; 2-Any serious medical or neurological problem; 3- IQ less than 70; 4- Substance dependence(except for nicotine and caffeine); 5- receiving ECT during the last 14 days,6-Depression Score less than 12 in Hamilton depression scale

Age

From **18 years** old to **50 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: 50

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tehran University of Medical Sciences

Street address

Keshvarz Blvd

City

Tehran

Postal code

Approval date

2014-09-23, 1393/07/01

Ethics committee reference number

26261

Health conditions studied

1

Description of health condition studied

schizophrenia

ICD-10 code

F20

ICD-10 code description

schizophrenia

Primary outcomes

1

Description

Severity of schizophrenia

Timepoint

Baseline and weeks 2-4-8 after beginig of treatment

Method of measurement

Positive and Negative Syndrome Scale (PANSS)

Secondary outcomes

1

Description

extrapyramidal side effects

Timepoint

Baseline and weeks 2-4-6-8 after beginig of treatment

Method of measurement

by Extrapyramidal Symptoms Rating Scale

Intervention groups

1

Description

Tablets Risperidone (4-6 mg/day) combined with 40 mg/day simvastatin as intervention group for 8 weeks

Category

Treatment - Drugs

2

Description

Tablet Risperidone (4-6 mg/day) combined with placebo as control group for 8 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Roozbeh Hospital

Full name of responsible person

Prof. Shahin Akhondzadeh

Street address

South Kregar street, Roozbeh Hospital

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Dr masoud yunesian

Street address

Keshvarz Blvd

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Prof. Shahin Akhondzadeh

Position

Prof. of Clinical Psychopharmacology

Other areas of specialty/work

Street address

South Kargar street; Roozbeh Hospital

City

Tehran

Postal code

Phone

+98 21 5541 2222

Fax

Email

s.akhond@sina.tums.ac.ir

s.akhond@neda.netsakhond@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Prof. Shahin Akhondzadeh

Position

Prof. of Clinical Psychopharmacology

Other areas of specialty/work

Street address

South Kargar Street; Roozbeh Hospital

City

Tehran

Postal code

Phone

+98 21 5541 2222

Fax

Email

sakhond@yahoo.com s.akhond@neda.net

s.akhond@sina.tums.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Prof. Shahin Akhondzadeh

Position

Prof. of Clinical Psychopharmacology

Other areas of specialty/work

Street address

South Karegar street; Roozbeh Hospital

City

Tehran

Postal code

Phone

00

Fax

Email

s.akhond@sina.tums.ac.ir

s.akhond@neda.netsakhond@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty